Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8) an open-label randomised controlled phase 3 trial
本文档由 4bn6gnsm57bt7ni4qxceb1_maj.. 分享于2016-06-18 08:41
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8) an open-label randomised controlled phase 3 trial
君,已阅读到文档的结尾了呢~~